Anti-VEGF Receptor 2/KDR Antibody Picoband®

Overview

This antibody is intended for detection of KDR (Vascular endothelial growth factor receptor 2) in biological samples using common immunoassay formats. It is typically selected based on target identity, species reactivity, clonality/clone information, and detection modality.

Vendor notes: Boster Bio Anti-VEGF Receptor 2/KDR Antibody Picoband® catalog # PB9429. Tested in WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Key elements and design rationale

• Antibody format: Rabbit Polyclonal Rabbit IgG
• Immunogen / epitope context: A synthetic peptide corresponding to a sequence at the N-terminus of human KDR, different from the related mouse and rat sequences by three amino acids.
• Molecular weight context: reported MW: 152 kDa; calculated MW: 151527 MW
• Reactivity: Human
• Applications: WB

As a polyclonal antibody, the reagent recognizes multiple epitopes on the target, which can improve detection robustness but may increase sensitivity to sample-dependent epitope changes.

Biological background

Vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 2. KDR (Kinase Insert Domain Receptor), also known as FLK1, VEGFR or VEGFR2, is a VEGF receptor. KDR is the human gene encoding it. Sait et al. (1995) likewise corrected the assignment to chromosome 4q11-q12 to the same region occupied also by PDGFRA and KIT, thus indicating the location of a cluster of receptor tyrosine kinase genes. Vascular endothelial growth factor (VEGF) is the only mitogen that specifically acts on endothelial cells. Its expression is upregulated by hypoxia, and its cell-surface receptor, known as fetal liver kinase-1 (Flk1) in mouse, is exclusively expressed in endothelial cells (Plate et al., 1993). Flk1 is the mouse homolog of KDR (Matthews et al., 1991). Functional note: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. . Reported localization: Cell junction . Endoplasmic reticulum . Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). . Expression/tissue context: Detected in cornea (at protein level). Widely expressed. .

Research relevance and current trends

• Angiogenesis: Researchers commonly examine how KDR (Vascular endothelial growth factor receptor 2) relates to this theme using model systems and orthogonal readouts.
• Cancer: Researchers commonly examine how KDR (Vascular endothelial growth factor receptor 2) relates to this theme using model systems and orthogonal readouts.
• Cancer Metabolism: Researchers commonly examine how KDR (Vascular endothelial growth factor receptor 2) relates to this theme using model systems and orthogonal readouts.

Common research applications

• Western blotting: compare relative KDR (Vascular endothelial growth factor receptor 2) levels across conditions; band patterns may reflect isoforms and processing.

Notes for experimental interpretation

• Specificity notes: No cross reactivity with other proteins.
• Cross-reactivity: No cross-reactivity with other proteins
• Family / similarity context: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
• Isoforms and PTMs: Apparent size and signal patterns can differ across splice isoforms, proteolytic processing, and post-translational modifications.
• Controls: Include an isotype control (as relevant), no-primary control for imaging, and orthogonal validation such as KD/KO samples when available.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.